Biopharma’s most promising startups in 2021
An extraordinary ferment of scientific activity over the last 20 years has spawned a new generation of biotech companies, dedicated to the pursuit of breakthrough therapies and the creation of important new pipelines. This will be our latest look at 11 of the most important up-and-coming private biotechs in the business, independently selected by company founder and editor John Carroll.
Award Presentation
The biotech 2.0 era has arrived. And with that backdrop, we'll unveil the top 11 companies supercharging a new generation of startups in 2021.
Watch John Carroll & John Chiminski as they talk biotech with the teams behind the winning companies and learn what defines the Endpoints 11.
John Carroll
Founder & Editor Endpoints News
John Chiminski
Chairman & CEO Catalent
Fireside Chat
The startup world in biotech has changed radically in the last few years. Now, the right scientists teamed with the right execs can raise hundreds of millions of dollars to back biotechs that are looking to develop breakthrough drugs with game-changing technology. We’ll explore the new rules of the investment game with some of the busiest players: Jürgen Eckhardt, the head of Leaps by Bayer, and Helen Kim, managing partner of Vida Ventures.
Jürgen Eckhardt
SVP and Head of Leaps by Bayer Bayer
Helen Kim
Senior Managing Director Vida Ventures
Jean-Francois
Formela
MD, Partner Atlas Venture
John Chiminski
Chairman & CEO Catalent
John Carroll
Founder & Editor Endpoints News
